Additionally, the A3 AR agonist FM-101 is under evaluation in early-phase studies for ocular hypertension and NASH [84], further illustrating the pharmacological versatility of this receptor subtype as a therapeutic target. Here, ADORA3 is linked to metabolic dysfunction-associated steatohepatitis.